333 LAKESIDE DR, FOSTER CITY, CA
Gilead Sciences Enters Eleventh Supplemental Indenture for $3B Notes
Announces First Quarter Financial Results
Gilead Sciences, Inc. Annual Meeting Results; Nine Directors Elected
Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-Cel
Annual Report to Security Holders
Sciences to Acquire to Maximize Long-Term Potential of Anito-cel
Announces Fourth Quarter and Full Year 2025 Financial Results
Executive Departure - Deborah H. Telman Exits Gilead Sciences
Q1
FY 2024
Q3
Q2
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Additional Proxy Materials
Definitive Proxy Statement
Additional Proxy Soliciting Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Quarterly Holdings Report for Institutional Managers
Free Writing Prospectus
Amended Tender Offer Statement by Third Party